



**Atty. Docket No.**  
**60390-AZ-PCT-**  
**US/JPW/GJG/NDP**

**Serial No.**  
**10/816,329**

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

**Applicants:**  
**Arlindo L. Castelhana, et al.**

**Filing Date**  
**March 31, 2004**

Group 1624

## U.S. PATENT DOCUMENTS

Examiner  
Initial

## FOREIGN PATENT DOCUMENTS

**Document Number**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

1

**EXAMINER**

**DATE CONSIDERED**

A/27/6,

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Arlindo L. Castelhana et al.  
Serial No.: 10/816,329  
Filed: March 31, 2004  
**Exhibit A**

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60390-AZ-PCT-  
US/JPW/GJG/JBC

Serial No.

Not Yet Known  
19816329INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants:  
Arlindo L. Castelhana, et al.Filing Date  
Herewith

Group

1624

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
gr	3 0 3 7 9 8 0	6/5/62	Hitchings, et al.;		1	
	3 9 1 0 9 1 3	10/7/75	Kim, et al.;			
	5 2 9 6 4 8 4	3/22/94	Coghlan, et al.;			
	5 4 0 9 9 3 0	4/25/95	Spada, et al.;			
	5 5 1 6 8 9 4	5/14/96	Reppert;			
	5 5 8 0 8 7 0	12/3/96	Barker, et al.;			
	5 6 4 6 1 3 0	7/8/97	Shi;			
	5 6 8 1 9 4 1	10/28/97	Cook, et al.;			
	5 6 3 9 9 1 3	6/17/97	Lidor, et al.;			
	5 6 4 6 1 5 6	7/8/97	Jacobson, et al.;			
	5 7 8 0 4 8 1	7/14/98	Jacobson, et al.;			
	5 7 1 0 1 5 8	1/20/98	Myers, et al.;			

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
gr WO 9 3 2 0 0 7 8	10/14/93	PCT;				
WO 9 4 1 7 0 9 0	8/4/94	PCT;				
WO 9 4 1 3 6 7 6	6/23/94	PCT;				
WO 9 4 2 4 1 3 6	10/27/94	PCT;				
WO 9 5 1 9 9 7 0	7/27/95	PCT;				
WO 9 5 1 1 6 8 1	5/4/95	PCT;				
WO 9 5 2 0 5 9 7	8/3/95	PCT;				
WO 9 5 1 9 7 7 4	7/27/95	PCT;				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

gr	Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A <sub>2</sub> Receptor". Ann. NY. Acad. Sci., 825: 11-22;
	Abbracchio M., et al., (1999) "Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases", Ann. NY. Acad. Sci., 890: 79-92;
	Banker, G.S. et al., Modern Pharmaceuticals, 3 <sup>rd</sup> ed., Marcel Dekker, New York, 1996, page 596 (Exhibit 5);
	Baraldi P., et al., (2000) "New potent and selective human adenosine A <sub>2</sub> receptor antagonists", Tips, 21: 456-459;

EXAMINER

DATE CONSIDERED

4/27/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60390-AZ-PCT-  
US/JPW/GJG/JBCSerial No.  
Not Yet  
KnownINFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants:  
Arlindo L. Castelhana, et al.Filing Date  
Herewith

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
A	5 7 1 4 4 9 3	2/3/98	Myers, et al.;			
	5 7 2 1 2 3 7	2/24/98	Myers, et al.;			
	5 7 4 7 4 9 8	5/5/98	Schnur, et al.;			
	5 7 8 0 4 5 0	7/14/98	Shade;			
	5 8 3 4 6 0 9	11/10/98	Horne, et al.;			
	5 8 7 7 2 1 8	3/2/99	Herzig, et al.;			
	5 8 7 7 2 2 1	3/2/99	Cohen, et al.;			
	5 8 8 0 1 5 9	3/9/99	Herzig, et al.;			
	5 9 1 4 3 4 9	6/22/99	Cohen, et al.;			
	5 9 9 4 4 0 8	11/30/99	Cohen, et al.;			
	5 9 6 2 4 5 8	10/5/99	Lohmann, et al.;			
	09 4 5 4 0 7 4	12/2/99	Castelhana, et al.;			
	6 6 6 4 2 5 2	12/16/03	Castelhana, et al.;			
	6 6 7 3 8 0 2	1/6/04	Castelhana, et al.;			
	6 6 8 0 3 2 4	1/20/04	Castelhana, et al.;			
	6 6 8 6 3 6 6	2/3/04	Castelhana, et al.;			
	6 1 0 3 8 9 9	8/15/00	Horne, et al.;			
	20 02 00 28 7 8 2	3/7/02	Castelhana, et al.;			

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Yes	No
WO 9 5 1 8 6 1 7	7/13/95	PCT;				
WO 9 6 1 9 4 7 8	6/27/96	PCT;				
WO 9 7 0 5 1 3 8	2/13/94	PCT;				
WO 9 7 3 3 8 7 9	9/18/97	PCT;				
WO 9 7 0 2 2 6 6	1/23/97	PCT;				
WO 9 8 0 7 7 2 6	2/26/98	PCT;				
WO 9 8 2 9 3 9 7	7/9/98	PCT;				
WO 9 8 5 7 6 5 1	12/23/98	PCT;				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Barrett, R.J. (1996) "Realizing the Potential of Adenosine-Receptor-Based Therapeutics" <u>Proc. West. Pharmacol. Soc.</u> 39: 61-66 (Exhibit 2);
Blazynski C., (1990) "Discrete Distributions of Adenosine Receptors in Mammalian Retina", <u>Journal of Neurochemistry</u> 53: 648-655;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-AZ-PCT- US/JPW/GJG/JBC		Serial No. <del>Not Yet</del> <del>Known</del> <span style="float: right; font-size: 1.5em;">10/8/02</span>	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo L. Castelhana, et al.			
					Filing Date Herewith		Group <span style="float: right; font-size: 1.5em;">1624</span>	

  

U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
<i>h</i>		20 02 00 94 9 7 4	7/18/02	Castelhana, et al.;					

  

FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
<i>h</i>	WO	9 8 0 8 3 8 2	3/5/98	PCT;					
	WO	9 8 2 2 4 6 5	5/28/98	PCT;					
	WO	9 9 0 6 0 5 3	2/11/99	PCT;					
	WO	9 9 0 8 4 6 0	2/18/99	PCT;					
	WO	9 9 3 3 8 1 5	7/18/99	PCT;					
	WO	9 9 4 2 0 9 3	8/26/99	PCT;					
	WO	9 9 6 2 5 1 8	12/9/99	PCT;					
<i>h</i>	WO	0 0 0 3 7 4 1	1/27/00	PCT;					

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>h</i>	Braas K.M., et al., (1987) "Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina", <u>Proceedings of the National Academy of Science</u> , 84: 3906-3910;
<i>h</i>	Bradford M. M., (1976) "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", <u>Anal. Biochem.</u> , 72: 248;
<i>h</i>	Brand A., et al., (2001) "Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons", <u>Neuropharmacology</u> , 40: 85-95;
<i>h</i>	Broach, J. R., et al., (1983) "Vectors for high level, inducible expression of cloned genes in yeast", Inouye (ed.), <u>Experimental Manipulation of Gene Expression</u> . Academic Press, New York, 83-117;
<i>h</i>	Bundy, G.L. et al. (1995) "Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity" <u>J. Med. Chem.</u> 38:4161-4163;
<i>h</i>	Casavola V., et al., (1998) "Adenosine A3 receptor activation increases cystolic calcium concentration via calcium influx in A6 cells", <u>Drug Development Research</u> , 43 (1): 62;
<i>h</i>	Chen, Y. L., et al., (1997) "Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyrimidine: A Centrally Active Corticotropin-Releasing Factor <sub>1</sub> Receptor Antagonist", <u>J. Med. Chem.</u> , 40: 1749-1754;
<i>h</i>	Cheng, Y. and Prusoff, W. H. (1973) "Relationship Between The Inhibition Constant ( $K_i$ ) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition ( $I_{50}$ ) Of An Enzymatic Reaction", <u>Biochem. Pharmacol.</u> , 22: 3099-3109;
<i>h</i>	Christianson, T. W. et al., (1992) "Multifunctional yeast high-copy-number shuttle vectors", <u>Gene</u> , 110: 119-122;
<i>h</i>	DeNinno, M.P. in <u>Annual Reports in Medicinal Chemistry</u> , Vol. 33, (Academic Press: San Diego, 1998), pp. 111-120;

  

EXAMINER <i>Don Mc G</i>	DATE CONSIDERED <i>4/27/05</i>
--------------------------	--------------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-AZ-PCT- US/JPW/GJG/JBC		Serial No. <del>Not Yet</del> Known						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Arlindo L. Castelhana, et al.								
					Filing Date Herewith		Group 1624						
					10816 329								
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate			
<b>FOREIGN PATENT DOCUMENTS</b>													
		Document Number				Date	Country	Class	Subclass	Trans lation			
										Yes No			
		EP	0	5	1	4	5	4	0	11/25/92	EPO;		
		EP	0	6	8	2	0	2	7	11/15/95	EPO;		
		EP	0	7	2	9	7	5	8	9/4/96	EPO;		
		EP	0	3	2	2	2	4	2	6/28/89	EPO;		
		EP	0	7	2	9	7	5	8	4/9/96	EPO;		
		EP	0	7	7	3	0	2	3	5/14/97	EPO;		
		IN	0	1	5	7	2	8	0	2/22/86	IN;		
		GB	0	9	1	5	3	0	3	1/9/63	GB		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Dooley, M.J. et al., "Theoretical Structure-Activity Studies of Adenosine A1 Ligands: Requirements for Receptor Affinity" <i>Bioorg. Med. Chem.</i> (1996), 4(6): 923-934;											
		Duzic, E. et al., (1992) "Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors", <i>J. Biol. Chem.</i> , 267: 9844-9851;											
		Ezeamuzie C., et al., (1999) "Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release", <i>British Journal of Pharmacology</i> , 127: 188-194;											
		Feoktistov, I. et al., (1998) "Adenosine A2B receptors: a novel therapeutic target in asthma?", <i>TIPS</i> 19: 148-153;											
		Fozard J., et al., (1996) "Mast cell degranulation following adenosine A3 receptor activation in rats", <i>European Journal of Pharmacology</i> , 298: 293-297;											
		Franco M., et al., (1999) "Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats", <i>Journal of the American Society of Nephrology</i> , 1681-1688;											
		GenBank accession # S46950;											
		GenBank accession numbers S45235 and S56143;											
EXAMINER <i>Tom McEl</i>		DATE CONSIDERED <i>4/27/01</i>											
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60390-AZ-PCT-  
US/IPW/GJG/JBCSerial No.  
~~Not Yet Known~~INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants:  
Arlindo L. Castelhana, et al.Filing Date  
Herewith

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
GM	3 1 4 5 2 8 7	5/19/93	GM;				
JP	9 2 9 1 0 8 9	5/11/99	JP;				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Guerra L., et al., (1998) "Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells", <u>Nephrology Dialysis Transplantation</u> , 13 (6): A5;
	Hart, H. et al., <u>Organic Chemistry, A Short Course</u> , (Houghton Mifflin: 1995), p. 121;
	International Search Report for International Application No. PCT/US99/12135;
	International Search Report for International Application No. PCT/US00/32702;
	Iwamura, H. et al. (1996) "Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists" <u>J. Med. Chem.</u> , 26: 838-844;
	Jacobson K.A., et al., (1997) "Pharmacological Characterization of Novel A3 Adenosine Receptor-selective Antagonists", <u>Neuropharmacology</u> , 36 (9): 1157-1165;
	Jacobson K.A., et al., (1998) "Adenosine A3 receptors: novel ligands and paradoxical effects", <u>Tips</u> , 19:184-191;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60390-AZ-PCT-  
US/JPW/GJG/JBCSerial No.  
~~Not Yet Known~~INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants:  
Arlindo L. Castelhana, et al.Filing Date  
Herewith

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>h</i>	Muller, C. E. et al. (1990) "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective Adenosine Receptor Antagonists" <u>J. Med. Chem.</u> , 33: 2822-2828;
	Muller, C. E. (1997) "A <sub>1</sub> -Adenosine Receptor Antagonists", <u>Exp. Opin. Ther. Patents</u> 7(5): 419-440;
	Muller, C. E., et al., (1997) "Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A <sub>2A</sub> -Selective Adenosine Receptor Antagonists", <u>J. Med. Chem.</u> , 40: 4396-4405;
	Muller, E. C. et al. (1996) "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A <sub>1</sub> -Adenosine Receptor Antagonist" <u>J. Med. Chem.</u> , 39: 2482-2491;
	Nyce J. W. and Metzger J. W., (1997) "DNA antisense therapy for asthma in an animal model", <u>Nature</u> , 385: 721-725;
	Ohana G., et al., (2001) "Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor", <u>Journal of Cellular Physiology</u> , 186: 19-23;
	PCT International Preliminary Examination Report for International Application No. PCT/US99/12135;

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





[illegible]

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60390-AZ-PCT-  
US/JPW/G.IG/JBCSerial No.  
Not Yet KnownINFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants:  
Arlindo L. Castelhana, et al.Filing Date  
Herewith

Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Y	Yao Y., et al., (1997) "Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists", <u>Biochemical And Biophysical Research Communications</u> , 232: 317-322;
Z	Zhao Z., et al., (2000) "A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice", <u>Biochimica et Biophysica Acta</u> , 1500: 280-290;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.